Join
Live feed
·
PRReleasevia Quantisnow
Celcuity Inc. logo

Celcuity's Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients

ByQuantisnow·Wall Street's wire, on your screen.
CELC· Celcuity Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CELC (Celcuity Inc.) and more on Quantisnow.